Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kura Oncology, Inc. KURA
$12.07
-$0.33 (-2.70%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
832897762.00000000
-
week52high
19.93
-
week52low
9.49
-
Revenue
0
-
P/E TTM
-6
-
Beta
0.88996500
-
EPS
-1.98000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | Outperform | 13 июл 2022 г. |
| Cantor Fitzgerald | Overweight | 12 июл 2022 г. | |
| SVB Leerink | Outperform | Outperform | 25 февр 2022 г. |
| Credit Suisse | Outperform | Outperform | 25 февр 2022 г. |
| Jefferies | Buy | 15 февр 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| FORD KATHLEEN | D | 21214 | 1821 | 27 янв 2023 г. |
| DOYLE THOMAS JAMES | D | 16841 | 866 | 27 янв 2023 г. |
| DOYLE THOMAS JAMES | D | 17707 | 682 | 27 янв 2023 г. |
| DALE STEPHEN | D | 27675 | 4840 | 27 янв 2023 г. |
| DALE STEPHEN | D | 32515 | 4385 | 27 янв 2023 г. |
| FLOWERS KIRSTEN | D | 20605 | 1906 | 27 янв 2023 г. |
| Bair Teresa Brophy | D | 0 | 2100 | 17 ноя 2022 г. |
| Collins Helen Louise | A | 23000 | 23000 | 21 июн 2022 г. |
| Parks Diane L. | A | 23000 | 23000 | 21 июн 2022 г. |
| SCHAFER CAROL | A | 23000 | 23000 | 21 июн 2022 г. |
Новостная лента
Kura Oncology, Inc. (KURA) Q1 2023 Earnings Call Transcript
Seeking Alpha
10 мая 2023 г. в 22:13
Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Pete De Spain - SVP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Thomas Doyle - SVP, Finance & Accounting Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Bradley Canino - Stifel, Nicolaus & Company Li Watsek - Cantor Fitzgerald & Co. Philip Nadeau - TD Cowen Operator Good afternoon, ladies and gentlemen, and welcome to the Q1 2023 Kura Oncology, Inc. Earnings Conference Call. [Operator Instructions].
Kura Oncology to Report First Quarter 2023 Financial Results
GlobeNewsWire
03 мая 2023 г. в 07:30
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
3 Under-the-Radar Stocks That AI Predicts Will Soar in May
InvestorPlace
01 мая 2023 г. в 14:07
Investors looking for help finding the best under-the-radar stocks may have a new ally: the AI chatbot. Using the prompt “publicly traded companies that may be on the cusp of breaking out in popularity in May 2023,” the chatbot created a list of five top stocks to dig into.
Kura Oncology to Participate in Upcoming Investor Conferences
GlobeNewsWire
01 мар 2023 г. в 07:30
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:
Kura Oncology, Inc. (KURA) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 22:11
Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations and Corporate Communications Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Finance and Accounting Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Group LLC Peter Lawson - Barclays Li Watsek - Cantor Fitzgerald, L.P. Bradley Canino - Stifel Financial Corp. Eva Privitera - Cowen Inc. Reni Benjamin - JMP Securities LLC Operator Greetings, and welcome to Kura Oncology's Fourth Quarter 2022 Earnings Conference Call.